Alpha-9 Oncology

Alpha-9 Oncology is a clinical-stage radiopharmaceutical company that spun out of the University of British Columbia and BC Cancer in 2019 to develop a portfolio of targeted cancer therapies. Alpha-9 engineers bespoke radiopharmaceutical molecules — optimizing the binder, linker, chelator, and radioisotope — to deliver radiation directly to tumor cells while limiting exposure to healthy tissue. The company operates purpose-built research facilities in Vancouver, BC and Boston, MA, and in October 2024 raised an oversubscribed $175M Series C led by Lightspeed Venture Partners and Ascenta Capital to advance its clinical pipeline. Alpha-9 is a drug developer and does not currently publish a public developer API; this profile captures its company identity and public-web surface for the API Evangelist network.

Alpha-9 Oncology is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Oncology, Radiopharmaceuticals, and Biotechnology.

Alpha-9 Oncology’s developer surface includes engineering blog, support, and 5 more developer resources.

🌐 Visit website 📡 Source on GitHub

15.0/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyHealthcareOncologyRadiopharmaceuticalsBiotechnologyCancer TherapyClinical StageDrug Development

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 15.0/100 · emerging

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/alpha-9-oncology: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 3

The organization behind the API

Website

Website

Blog

Blog

LinkedIn

Source (apis.yml)

aid: alpha-9-oncology
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/alpha-9-oncology.png
name: Alpha-9 Oncology
description: Alpha-9 Oncology is a clinical-stage radiopharmaceutical company that spun out of the University of British Columbia
  and BC Cancer in 2019 to develop a portfolio of targeted cancer therapies. Alpha-9 engineers bespoke radiopharmaceutical
  molecules — optimizing the binder, linker, chelator, and radioisotope — to deliver radiation directly to tumor cells while
  limiting exposure to healthy tissue. The company operates purpose-built research facilities in Vancouver, BC and Boston,
  MA, and in October 2024 raised an oversubscribed $175M Series C led by Lightspeed Venture Partners and Ascenta Capital to
  advance its clinical pipeline. Alpha-9 is a drug developer and does not currently publish a public developer API; this profile
  captures its company identity and public-web surface for the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/alpha-9-oncology/refs/heads/main/apis.yml
x-type: company
x-source: general-catalyst-portfolio
x-tier: stub
x-tier-reason: portfolio-lead
x-api-surface: none
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Healthcare
- Oncology
- Radiopharmaceuticals
- Biotechnology
- Cancer Therapy
- Clinical Stage
- Drug Development
apis: []
common:
- type: DomainSecurity
  url: security/alpha-9-oncology-domain-security.yml
- type: Website
  url: https://www.a9oncology.com/
- type: Blog
  name: News & Events
  url: https://www.a9oncology.com/news/
- type: Support
  name: Contact
  url: https://www.a9oncology.com/contact/
- type: PrivacyPolicy
  url: https://www.a9oncology.com/privacy-policy/
- type: TermsOfService
  url: https://www.a9oncology.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/alpha9tx/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence